Anti-CD2 x Anti-TCR (Vβ8) Bispecific Antibody (IgG-IgG) (BSIG-H223)

Anti-CD2 x Anti-TCR (Vβ8) Bispecific Antibody (IgG-IgG) is designed to be generated by crosslinking two full length IgGs, anti-CD2 and anti-TCR (Vβ8) parental antibodies. A stable linkage is formed between the two antibodies. This BsAb can activate T cells. It is designed for the research of Tumors therapy.

Datasheet

Specifications

Targets

CD2 & TCR (Vβ8)

Type

IgG-IgG

Species Reactivity

Mouse

Target 1

CD2

Host Animal 1

Human

Target 2

TCR (Vβ8)

Host Animal 2

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Tumors

Targets

Target 1

CD2

Gene ID

12481

UniProt ID

P06729

Alternative Names

CD2; CD2 molecule; T11; SRBC; LFA-2; T-cell surface antigen CD2; leukocyte function-associated antigen-2; LFA-3 receptor; rosette receptor; erythrocyte receptor; lymphocyte-function antigen-2; T-cell surface antigen T11/Leu-5; CD2 antigen (p50), sheep red blood cell receptor

Target 2

TCR (Vβ8)

Gene ID

100124664

Alternative Names

Trbv8; T cell receptor beta variable 8; TCR; T-cell receptor

Our services and products are only for lab research, not for any diagnostic or therapeutic use.

Welcome! For price inquiries, we will get back to you as soon as possible.

To order, please email

INQUIRY

Online Inquiry

USA
45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-381-2994
Fax: 1-631-207-8356
Email:

Germany
Heidenkampsweg 58, 20097 Hamburg, Germany
Email:

UK
167-169 Great Portland Street, 5th Floor, London, W1W 5PE
Tel: 44-207-097-1828
Email: